376 related articles for article (PubMed ID: 31036012)
1. Health outcomes and unmet needs in patients with long-standing rheumatoid arthritis attending tertiary care in Greece: a cohort study.
Boumpas DT; Sidiropoulos P; Settas L; Szczypa P; Tsekouras V; Hernandez Daly AC
Health Qual Life Outcomes; 2019 Apr; 17(1):73. PubMed ID: 31036012
[TBL] [Abstract][Full Text] [Related]
2. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission with Six Months of Biological DMARDs Treatment.
Miwa Y; Takahashi R; Ikari Y; Maeoka A; Nishimi S; Oguro N; Hayashi T; Hatano M; Isojima S; Yanai R; Kasama T; Toyoshima Y; Inagaki K; Sanada K
Intern Med; 2017; 56(8):903-906. PubMed ID: 28420837
[TBL] [Abstract][Full Text] [Related]
3. Health-Related Quality of Life and Functional Ability of Patients with Rheumatoid Arthritis: A Study from a Tertiary Care Hospital in Thailand.
Munchey R; Pongmesa T
Value Health Reg Issues; 2018 May; 15():76-81. PubMed ID: 29474183
[TBL] [Abstract][Full Text] [Related]
4. EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry.
Jørgensen TS; Turesson C; Kapetanovic M; Englund M; Turkiewicz A; Christensen R; Bliddal H; Geborek P; Kristensen LE
PLoS One; 2017; 12(2):e0169946. PubMed ID: 28151971
[TBL] [Abstract][Full Text] [Related]
5. Treatment with the first TNF inhibitor in rheumatoid arthritis patients in the Hellenic Registry of Biologic Therapies improves quality of life especially in young patients with better baseline functional status.
Boubouchairopoulou N; Flouri I; Drosos AA; Boki K; Settas L; Zisopoulos D; Skopouli FN; Papadopoulos I; Iliopoulos A; Kyriopoulos J; Boumpas DT; Athanasakis K; Sidiropoulos P
Clin Exp Rheumatol; 2016; 34(6):999-1005. PubMed ID: 27749220
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
[TBL] [Abstract][Full Text] [Related]
7. Impact of socio-demographic and clinical characteristics on functional disability and health-related quality of life in patients with rheumatoid arthritis: a cross-sectional study from Palestine.
Al-Jabi SW; Seleit DI; Badran A; Koni A; Zyoud SH
Health Qual Life Outcomes; 2021 Oct; 19(1):241. PubMed ID: 34645455
[TBL] [Abstract][Full Text] [Related]
8. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.
Dasgupta B; Combe B; Louw I; Wollenhaupt J; Zerbini CA; Beaulieu A; Schulze-Koops H; Durez P; Wolff V; Yao R; Weng HH; Govoni M; Vastesaeger N
Arthritis Care Res (Hoboken); 2014 Dec; 66(12):1799-807. PubMed ID: 24839031
[TBL] [Abstract][Full Text] [Related]
9. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics of Rheumatoid Arthritis Patients Achieving Functional Remission after Six Months of Non-tumor Necrosis Factor Biological Disease-Modifying Antirheumatic Drugs (DMARDs) Treatment.
Miwa Y; Saito M; Furuya H; Yanai R; Ikari Y; Hayashi T; Kasama T; Toyoshima Y; Inagaki K
Intern Med; 2017 Sep; 56(17):2271-2275. PubMed ID: 28794381
[TBL] [Abstract][Full Text] [Related]
11. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice.
Linde L; Sørensen J; Østergaard M; Hetland ML
J Rheumatol; 2013 Sep; 40(9):1479-86. PubMed ID: 23818719
[TBL] [Abstract][Full Text] [Related]
12. Impact of biologic DMARDs on quality of life: 12-month results of a rheumatic diseases cohort using the Brazilian EQ-5D tariff.
Alves de Oliveira Junior H; Pereira da Veiga T; Acurcio FA; Almeida AM; Ribeiro Dos Santos JB; da Silva MRR; Kakehasi AM; Cherchiglia ML
Hosp Pract (1995); 2020 Oct; 48(4):213-222. PubMed ID: 32567403
[TBL] [Abstract][Full Text] [Related]
13. The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study.
Psaltis D; Settas L; Georgiadis A; Koukli E; Bounas A; Livieratos A; Petrikkou E; Kalogiannaki H; Repa A; Vassilopoulos D; Sidiropoulos P
Rheumatol Int; 2022 Apr; 42(4):639-650. PubMed ID: 35091757
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
15. Influence of Biological Therapeutics on Patient-Reported Quality-Of-Life Outcomes (Whoqol-Bref), Functional Scores and Disease Activity among Croatian Patients with Rheumatoid Arthritis: Our Experience.
Gudelj Gračanin A; Matić A; Mikula T; Dobša J; Žagar I; Mužinić Marinić L; Morović-Vergles J
Psychiatr Danub; 2020 Nov; 32(Suppl 4):547-552. PubMed ID: 33212462
[TBL] [Abstract][Full Text] [Related]
16. Costs in Relation to Disability, Disease Activity, and Health-related Quality of Life in Rheumatoid Arthritis: Observational Data from Southern Sweden.
Wallman JK; Eriksson JK; Nilsson JÅ; Olofsson T; Kristensen LE; Neovius M; Geborek P
J Rheumatol; 2016 Jul; 43(7):1292-9. PubMed ID: 27252420
[TBL] [Abstract][Full Text] [Related]
17. Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
Blauvelt A; Leonardi CL; Gaylis N; Jauch-Lembach J; Balfour A; Lemke L; Hachaichi S; Brueckmann I; Festini T; Wiland P
BioDrugs; 2021 Mar; 35(2):229-238. PubMed ID: 33651341
[TBL] [Abstract][Full Text] [Related]
18. Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study.
Tanaka Y; Kameda H; Saito K; Kaneko Y; Tanaka E; Yasuda S; Tamura N; Fujio K; Fujii T; Kojima T; Anzai T; Hamada C; Fujino Y; Matsuda S; Kohsaka H
Arthritis Res Ther; 2018 Jul; 20(1):151. PubMed ID: 30029613
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months.
Bae SC; Cho SK; Won S; Lee HS; Lee SH; Kang YM; Lee SH; Lee YA; Choe JY; Chung WT; Suh CH; Shim SC; Lee J; Yoon BY; Kim DW; Lee SS; Yoo WH; Kim JS; Jung YO; Nah SS; Lee CK; Song GG; Choi SJ; Joung CI; Koh H; Kim YJ
Int J Rheum Dis; 2018 May; 21(5):1001-1009. PubMed ID: 29878615
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with disability in patients with rheumatoid arthritis with persistent moderate disease activity: a retrospective cohort study.
Scott IC; Mount J; Barry J; Kirkham B
BMC Rheumatol; 2020; 4():63. PubMed ID: 33094270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
